<DOC>
	<DOCNO>NCT00581971</DOCNO>
	<brief_summary>This single-institution , open-label , non-randomized phase IB/II trial celecoxib administer concurrently carboplatin , paclitaxel , radiation therapy patient locally advanced recurrent squamous cell carcinoma head neck .</brief_summary>
	<brief_title>Radiosensitization With Celecoxib Chemoradiation Head Neck Cancer</brief_title>
	<detailed_description>Treatment protocol consist radiotherapy , 70.2Gy , 1.8Gy qd , Monday Friday.Celecoxib 400mg bid take radiotherapy , start 1 week radiotherapy . Carboplatin IV , AUC 2.0 , weekly week 1 7 , Paclitaxel 45 mg/m2 , weekly week 1 7 , Celecoxib 400mg bid , continue therapy two year disease progression .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Histologically proven primary squamous cell carcinoma arise oropharynx , oral cavity , hypopharynx , larynx . Patients recurrences primary surgery ( history radiotherapy chemotherapy ) also eligible . The patient stage III IV disease , T3 high , N2 high , nonmetastatic . Recurrent need satisfy stag requirement restate , patient must nonmetastatic , either unresectable , medically inoperable , refuse surgery . Performance status &lt; 2 ( ECOG scale ) life expectancy &gt; 12 month . Age &gt; 19 year . The patient medically fit tolerate course definitive radiation therapy . The patient : adequate hepatic function bilirubin &lt; 1.5 x upper limit normal ( ULN ) , transaminase ( SGOT SGPT ) may 2.5 x ULN alkaline phosphatase &lt; ULN , alkaline phosphatase may 4 x ULN transaminases &lt; ULN , adequate renal function serum creatinine &lt; 1.5 mg/dl ( estimate creatinine clearance &gt; 50 mL/min ) , normal serum calcium , adequate hematologic function : define absolute neutrophil count &gt; 1500/ml , hematocrit &gt; 24 % , platelet count &gt; 100,000/ml . Patients hematocrit 24 % 30 % undergo transfusion treatment epoetin , may enrol . The patient may prior malignancy must diseasefree 5 year prior study entry . A history superficial nonmelanoma skin cancer situ carcinoma cervix less three year allow . The patient must agree use effective contraception procreative potential exists , continue contraception least 3 month follow completion study . Patient must inform investigational nature study sign inform consent form . The patient receive radiation therapy previously head neck . Previous radiotherapy skin cancer head neck permit field overlap . The patient receive prior chemotherapy head neck cancer . The patient pregnant lactating . Squamous cell carcinoma arise nasopharynx , sinus , salivary gland , primary unknown . Nonsquamous histology ( adenoid cystic mucoepidermoid ) Peripheral neuropathy &gt; Grade 2 . Serious nonmalignant disease ( e.g . congestive heart failure , uncontrolled atrial fibrillation , active hepatitis , renal failure renal transplant ) . Scleroderma active connective disorder ( Lupus ) Allergy celecoxib , sulfonamide , NSAIDS Any underlying psychological condition would prohibit understanding rendering informed consent . Major surgery &lt; 3 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Radiosensitization</keyword>
	<keyword>COX-2 inhibitor</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Chemoradiation</keyword>
</DOC>